{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:01:53Z","timestamp":1790755313627,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"DOI":"10.1007\/s00393-026-01880-8","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:42:24Z","timestamp":1790754144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Wie h\u00e4ufig erf\u00fcllen Patientinnen mit einer Sj\u00f6gren-Erkrankung die Aktivit\u00e4tskriterien f\u00fcr eine immunmodulatorische Behandlung?","How often do patients with Sj\u00f6gren\u02bcs syndrome fulfil the activity criteria for immunomodulatory treatment?"],"prefix":"10.1007","author":[{"given":"K.","family":"Karberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-5095","authenticated-orcid":false,"given":"J.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1880_CR1","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMcp1702514","volume":"378","author":"X Mariette","year":"2018","unstructured":"Mariette\u00a0X, Criswell\u00a0LA (2018) Primary Sj\u00f6gren\u2019s Syndrome. N Engl J Med 378:931\u2013939","journal-title":"N Engl J Med"},{"issue":"10320","key":"1880_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(21)02644-1","volume":"399","author":"A Saraux","year":"2022","unstructured":"Saraux\u00a0A, Devauchelle-Pensec\u00a0V (2022) Primary Sj\u00f6gren\u2019s syndrome: new beginning for evidence-based trials. Lancet 399(10320):121\u2013122 (Epub 2021 Nov 30)","journal-title":"Lancet"},{"issue":"5","key":"1880_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","volume":"78","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner\u00a0T, Posch\u00a0MG, Li\u00a0Y, Petricoul\u00a0O, Cabanski\u00a0M, Milojevic\u00a0JM, Kamphausen\u00a0E, Valentin\u00a0MA, Simonett\u00a0C, Mooney\u00a0L, H\u00fcser\u00a0A, Gram\u00a0H, Wagner\u00a0FD, Oliver\u00a0SJ (2019) Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis 78(5):641\u2013647 (Epub 2019 Mar 2)","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1880_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.43059","volume":"77","author":"T D\u00f6rner","year":"2025","unstructured":"D\u00f6rner\u00a0T, Bowman\u00a0SJ, Fox\u00a0R, Mariette\u00a0X, Papas\u00a0A, Grader-Beck\u00a0T, Fisher\u00a0BA, Barcelos\u00a0F, De Vita\u00a0S, Schulze-Koops\u00a0H, Moots\u00a0RJ, Junge\u00a0G, Woznicki\u00a0J, Sopala\u00a0M, Avrameas\u00a0A, Luo\u00a0WL, Hueber\u00a0W (2025) Safety and Efficacy of Ianalumab in Patients With Sj\u00f6gren\u2019s Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study. Arthritis Rheumatol 77(5):560\u2013570","journal-title":"Arthritis Rheumatol"},{"issue":"10320","key":"1880_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","volume":"399","author":"SJ Bowman","year":"2022","unstructured":"Bowman\u00a0SJ, Fox\u00a0R, D\u00f6rner\u00a0T, Mariette\u00a0X, Papas\u00a0A, Grader-Beck\u00a0T, Fisher\u00a0BA, Barcelos\u00a0F, De Vita\u00a0S, Schulze-Koops\u00a0H, Moots\u00a0RJ, Junge\u00a0G, Woznicki\u00a0JN, Sopala\u00a0MA, Luo\u00a0WL, Hueber\u00a0W (2022) Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399(10320):161\u2013171 (Epub 2021 Nov 30. Erratum in: Lancet. 2025 Mar 29; 405 (10484):1056)","journal-title":"Lancet"},{"issue":"3","key":"1880_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ard.2025.11.015","volume":"85","author":"N Agmon-Levin","year":"2026","unstructured":"Agmon-Levin\u00a0N, Ignatenko\u00a0S, Gordienko\u00a0A, Cort\u00e9s-Hern\u00e1ndez\u00a0J, Narongroeknawin\u00a0P, Romanowska-Pr\u00f3chnicka\u00a0K, Shen\u00a0N, Cifersk\u00e1\u00a0H, Kodera\u00a0M, Cheng-Chung\u00a0WJ, Leszczynski\u00a0P, Lan\u00a0JL, Mysler\u00a0E, Wojciechowski\u00a0R, Tarr\u00a0T, Vishneva\u00a0E, Chen\u00a0YH, Kaneko\u00a0Y, Finzel\u00a0S, Hoi\u00a0A, Okada\u00a0M, Koolvisoot\u00a0A, Lee\u00a0SS, Lie\u00a0D, Kaneko\u00a0H, Rojkovich\u00a0B, Sun\u00a0L, Zotkin\u00a0E, Viallard\u00a0JF, L\u00f3pez\u00a0BPM, Ghanshani\u00a0SA, Lau\u00a0C, Avrameas\u00a0A, Sips\u00a0C, Oliver\u00a0SJ (2026) B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. Ann Rheum Dis 85(3):476\u2013488 (Epub 2025 Dec 5)","journal-title":"Ann Rheum Dis"},{"issue":"10452","key":"1880_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","volume":"404","author":"BA Fisher","year":"2024","unstructured":"Fisher\u00a0BA, Mariette\u00a0X, Papas\u00a0A, Grader-Beck\u00a0T, Bootsma\u00a0H, Ng\u00a0WF, van Daele\u00a0PLA, Finzel\u00a0S, Noaiseh\u00a0G, Elgueta\u00a0S, Hermann\u00a0J, McCoy\u00a0SS, Akpek\u00a0E, Bookman\u00a0A, Sopala\u00a0M, Montecchi-Palmer\u00a0M, Luo\u00a0WL, Scheurer\u00a0C, Hueber\u00a0W, TWINSS study group (2024) Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet 404(10452):540\u2013553 (Epub 2024 Jul 31)","journal-title":"Lancet"},{"issue":"1","key":"1880_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000022","volume":"1","author":"R Seror","year":"2015","unstructured":"Seror\u00a0R, Bowman\u00a0SJ, Brito-Zeron\u00a0P, Theander\u00a0E, Bootsma\u00a0H, Tzioufas\u00a0A, Gottenberg\u00a0JE, Ramos-Casals\u00a0M, D\u00f6rner\u00a0T, Ravaud\u00a0P, Vitali\u00a0C, Mariette\u00a0X, Asmussen\u00a0K, Jacobsen\u00a0S, Bartoloni\u00a0E, Gerli\u00a0R, Bijlsma\u00a0JW, Kruize\u00a0AA, Bombardieri\u00a0S, Bookman\u00a0A, Kallenberg\u00a0C, Meiners\u00a0P, Brun\u00a0JG, Jonsson\u00a0R, Caporali\u00a0R, Carsons\u00a0S, De Vita\u00a0S, Del Papa\u00a0N, Devauchelle\u00a0V, Saraux\u00a0A, Fauchais\u00a0AL, Sibilia\u00a0J, Hachulla\u00a0E, Illei\u00a0G, Isenberg\u00a0D, Jones\u00a0A, Manoussakis\u00a0M, Mandl\u00a0T, Jacobsson\u00a0L, Demoulins\u00a0F, Montecucco\u00a0C, Ng\u00a0WF, Nishiyama\u00a0S, Omdal\u00a0R, Parke\u00a0A, Praprotnik\u00a0S, Tomsic\u00a0M, Price\u00a0E, Scofield\u00a0H, Sivils\u00a0LK, Smolen\u00a0J, Laqu\u00e9\u00a0RS, Steinfeld\u00a0S, Sutcliffe\u00a0N, Sumida\u00a0T, Valesini\u00a0G, Valim\u00a0V, Vivino\u00a0FB, Vollenweider\u00a0C (2015) EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a\u00a0user guide. RMD Open 1(1):e000022","journal-title":"RMD Open"},{"issue":"6","key":"1880_CR9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","volume":"70","author":"R Seror","year":"2011","unstructured":"Seror\u00a0R, Ravaud\u00a0P, Mariette\u00a0X, Bootsma\u00a0H, Theander\u00a0E, Hansen\u00a0A, Ramos-Casals\u00a0M, D\u00f6rner\u00a0T, Bombardieri\u00a0S, Hachulla\u00a0E, Brun\u00a0JG, Kruize\u00a0AA, Praprotnik\u00a0S, Tomsic\u00a0M, Gottenberg\u00a0JE, Devauchelle\u00a0V, Devita\u00a0S, Vollenweider\u00a0C, Mandl\u00a0T, Tzioufas\u00a0A, Carsons\u00a0S, Saraux\u00a0A, Sutcliffe\u00a0N, Vitali\u00a0C, Bowman\u00a0SJ, EULAR Sj\u00f6gren\u2019s Task Force (2011) EULAR Sjogren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren\u2019s syndrome. Ann Rheum Dis 70(6):968\u2013972 (Epub 2011 Feb 22)","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1880_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","volume":"74","author":"R Seror","year":"2015","unstructured":"Seror\u00a0R, Theander\u00a0E, Brun\u00a0JG, Ramos-Casals\u00a0M, Valim\u00a0V, D\u00f6rner\u00a0T, Bootsma\u00a0H, Tzioufas\u00a0A, Solans-Laqu\u00e9\u00a0R, Mandl\u00a0T, Gottenberg\u00a0JE, Hachulla\u00a0E, Sivils\u00a0KL, Ng\u00a0WF, Fauchais\u00a0AL, Bombardieri\u00a0S, Valesini\u00a0G, Bartoloni\u00a0E, Saraux\u00a0A, Tomsic\u00a0M, Sumida\u00a0T, Nishiyama\u00a0S, Caporali\u00a0R, Kruize\u00a0AA, Vollenweider\u00a0C, Ravaud\u00a0P, Vitali\u00a0C, Mariette\u00a0X, Bowman\u00a0SJ, EULAR Sj\u00f6gren\u2019s Task Force (2015) Validation of EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74(5):859\u2013866 (Epub 2014 Jan 17)","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1880_CR11","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1136\/annrheumdis-2015-208504","volume":"75","author":"R Seror","year":"2016","unstructured":"Seror\u00a0R, Meiners\u00a0P, Baron\u00a0G, Bootsma\u00a0H, Bowman\u00a0SJ, Vitali\u00a0C, Gottenberg\u00a0JE, Theander\u00a0E, Tzioufas\u00a0A, De Vita\u00a0S, Ramos-Casals\u00a0M, D\u00f6rner\u00a0T, Quartuccio\u00a0L, Ravaud\u00a0P, Mariette\u00a0X, EULAR Sj\u00f6gren Task Force (2016) Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Ann Rheum Dis 75(11):1945\u20131950 (Epub 2016 Jan 25)","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1880_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski\u00a0CH, Shiboski\u00a0SC, Seror\u00a0R, Criswell\u00a0LA, Labetoulle\u00a0M, Lietman\u00a0TM, Rasmussen\u00a0A, Scofield\u00a0H, Vitali\u00a0C, Bowman\u00a0SJ, Mariette\u00a0X, International Sj\u00f6gren\u2019s Syndrome Criteria Working Group (2017) 2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Primary Sj\u00f6gren\u2019s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol 69(1):35\u201345","journal-title":"Arthritis Rheumatol"},{"key":"1880_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41584-025-01268-z","volume":"21","author":"M Ramos-Casals","year":"2025","unstructured":"Ramos-Casals\u00a0M, Baer\u00a0AN, Brito-Zer\u00f3n\u00a0MDP, Hammitt\u00a0KM, Bouillot\u00a0C, Retamozo\u00a0S, Mackey\u00a0A, Yarowsky\u00a0D, Turner\u00a0B, Blanck\u00a0J, Fisher\u00a0BA, Akpek\u00a0EK, Baldini\u00a0C, Bootsma\u00a0H, Bowman\u00a0SJ, D\u00f6rner\u00a0T, Laing\u00a0L, Lieberman\u00a0SM, Mariette\u00a0X, Pflugfelder\u00a0SC, Sankar\u00a0V, Sis\u00f3-Almirall\u00a0A, Tzioufas\u00a0AG, Anaya\u00a0JM, Arma\u011fan\u00a0B, Bombardieri\u00a0M, Carsons\u00a0S, de Vita\u00a0S, Fox\u00a0RI, Gerli\u00a0R, Giacomelli\u00a0R, Gottenberg\u00a0JE, Hern\u00e1ndez-Molina\u00a0G, Jonsson\u00a0R, Kruize\u00a0A, Kwok\u00a0SK, Li\u00a0X, McCoy\u00a0SS, Ng\u00a0WF, Olsson\u00a0P, Rischmueller\u00a0M, Saraux\u00a0A, Scofield\u00a0RH, Valim\u00a0V, Vitali\u00a0C, Vivino\u00a0F, Wahren-Herlenius\u00a0M, Moutsopoulos\u00a0HM, International Task Force on Nomenclature of Sj\u00f6gren Disease (2025) 2023 International Rome consensus for the nomenclature of Sjoegren disease. Nat Rev Rheumatol 21:426\u2013437","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1880_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.2014.7682","volume":"312","author":"JE Gottenberg","year":"2014","unstructured":"Gottenberg\u00a0JE, Ravaud\u00a0P, Pu\u00e9chal\u00a0X, Le Guern\u00a0V, Sibilia\u00a0J, Goeb\u00a0V, Larroche\u00a0C, Dubost\u00a0JJ, Rist\u00a0S, Saraux\u00a0A, Devauchelle-Pensec\u00a0V, Morel\u00a0J, Hayem\u00a0G, Hatron\u00a0P, Perdriger\u00a0A, Sene\u00a0D, Zarnitsky\u00a0C, Batouche\u00a0D, Furlan\u00a0V, Benessiano\u00a0J, Perrodeau\u00a0E, Seror\u00a0R, Mariette\u00a0X (2014) Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial. JAMA 312(3):249\u2013258","journal-title":"JAMA"},{"issue":"4","key":"1880_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec\u00a0V, Mariette\u00a0X, Jousse-Joulin\u00a0S, Berthelot\u00a0JM, Perdriger\u00a0A, Pu\u00e9chal\u00a0X, Le Guern\u00a0V, Sibilia\u00a0J, Gottenberg\u00a0JE, Chiche\u00a0L, Hachulla\u00a0E, Hatron\u00a0PY, Goeb\u00a0V, Hayem\u00a0G, Morel\u00a0J, Zarnitsky\u00a0C, Dubost\u00a0JJ, Pers\u00a0JO, Nowak\u00a0E, Saraux\u00a0A (2014) Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann Intern Med 160(4):233\u2013242","journal-title":"Ann Intern Med"},{"issue":"6","key":"1880_CR16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","volume":"72","author":"JE Gottenberg","year":"2013","unstructured":"Gottenberg\u00a0JE, Cinquetti\u00a0G, Larroche\u00a0C, Combe\u00a0B, Hachulla\u00a0E, Meyer\u00a0O, Pertuiset\u00a0E, Kaplanski\u00a0G, Chiche\u00a0L, Berthelot\u00a0JM, Gombert\u00a0B, Goupille\u00a0P, Marcelli\u00a0C, Feuillet\u00a0S, Leone\u00a0J, Sibilia\u00a0J, Zarnitsky\u00a0C, Carli\u00a0P, Rist\u00a0S, Gaudin\u00a0P, Salliot\u00a0C, Piperno\u00a0M, Deplas\u00a0A, Breban\u00a0M, Lequerre\u00a0T, Richette\u00a0P, Ghiringhelli\u00a0C, Hamidou\u00a0M, Ravaud\u00a0P, Mariette\u00a0X, Club Rhumatismes et Inflammations and the French Society of Rheumatology (2013) Efficacy of rituximab in systemic manifestations of primary Sjogren\u2019s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 72(6):1026\u20131031 (Epub 2012 Dec 21)","journal-title":"Ann Rheum Dis"},{"key":"1880_CR17","doi-asserted-by":"crossref","unstructured":"Braun J, D\u00f6rner Th (2026) Praktisches Management der Sj\u00f6gren-Erkrankung im Zeitalter neuer Therapieoptionen. Aktueller Stellenwert der verf\u00fcgbaren Outcome-Parameter. Z Rheumatol 2026","DOI":"10.1007\/s00393-026-01799-0"},{"issue":"2","key":"1880_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.chest.2020.10.011","volume":"159","author":"AS Lee","year":"2021","unstructured":"Lee\u00a0AS, Scofield\u00a0RH, Hammitt\u00a0KM, Gupta\u00a0N, Thomas\u00a0DE, Moua\u00a0T, Ussavarungsi\u00a0K, St Clair\u00a0EW, Meehan\u00a0R, Dunleavy\u00a0K, Makara\u00a0M, Carsons\u00a0SE, Carteron\u00a0NL, Consensus Expert Panel (CEP) Members (2021) Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sj\u00f6gren\u2019s. Chest 159(2):683\u2013698 (Epub 2020 Oct 16)","journal-title":"Chest"},{"issue":"8","key":"1880_CR19","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","volume":"3","author":"S Arends","year":"2021","unstructured":"Arends\u00a0S, de Wolff\u00a0L, van Nimwegen\u00a0JF, Verstappen\u00a0GMPJ, Vehof\u00a0J, Bombardieri\u00a0M, Bowman\u00a0SJ, Pontarini\u00a0E, Baer\u00a0AN, Nys\u00a0M, Gottenberg\u00a0JE, Felten\u00a0R, Ray\u00a0N, Vissink\u00a0A, Kroese\u00a0FGM, Bootsma\u00a0H (2021) Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol 3(8):e553\u2013e562 (Epub 2021 May 26)","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"1880_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","volume":"81","author":"R Seror","year":"2022","unstructured":"Seror\u00a0R, Baron\u00a0G, Camus\u00a0M, Cornec\u00a0D, Perrodeau\u00a0E, Bowman\u00a0SJ, Bombardieri\u00a0M, Bootsma\u00a0H, Gottenberg\u00a0JE, Fisher\u00a0B, Hueber\u00a0W, van Roon\u00a0JA, Devauchelle-Pensec\u00a0V, Gergely\u00a0P, Mariette\u00a0X, Porcher\u00a0R, NECESSITY WP5 - STAR development working group, NECESSITY WP5- STAR development working group (2022) Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 81(7):979\u2013989 (Epub 2022 Apr 7)","journal-title":"Ann Rheum Dis"},{"key":"1880_CR21","doi-asserted-by":"crossref","unstructured":"Yang M, Lu Y, Wang S, Lin S. Efficacy and safety of pharmacological treatment for Sj\u00f6gren\u2019s disease: a\u00a0network meta-analysis. Z Rheumatol. 2026 May 11. Epub ahead of print.","DOI":"10.1007\/s00393-026-01824-2"},{"issue":"5","key":"1880_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15051945","volume":"15","author":"L Meudec","year":"2026","unstructured":"Meudec\u00a0L, Nocturne\u00a0G, Mariette\u00a0X (2026) Update on the Aetiopathogenesis of Sj\u00f6gren Disease: From Interferon Signaling to Epithelial Dysfunction. J\u00a0Clin Med 15(5):1945","journal-title":"J Clin Med"},{"issue":"1","key":"1880_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1475-x","volume":"19","author":"M Le Goff","year":"2017","unstructured":"Le Goff\u00a0M, Cornec\u00a0D, Jousse-Joulin\u00a0S, Guellec\u00a0D, Costa\u00a0S, Marhadour\u00a0T, Le Berre\u00a0R, Genestet\u00a0S, Cochener\u00a0B, Boisrame-Gastrin\u00a0S, Renaudineau\u00a0Y, Pers\u00a0JO, Saraux\u00a0A, Devauchelle-Pensec\u00a0V (2017) Comparison of 2002 AECG and 2016 ACR\/EULAR classification criteria and added value of salivary gland ultrasonography in a\u00a0patient cohort with suspected primary Sj\u00f6gren\u2019s syndrome. Arthritis Res Ther 19(1):269","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"1880_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/jcp.21.5.656","volume":"21","author":"DM Chisholm","year":"1968","unstructured":"Chisholm\u00a0DM, Mason\u00a0DK (1968) Labial salivary gland biopsy in Sj\u00f6gren\u2019s disease. J\u00a0Clin Pathol 21(5):656\u2013660","journal-title":"J Clin Pathol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01880-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:42:26Z","timestamp":1790754146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01880-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":24,"alternative-id":["1880"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01880-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.\u00a0Karberg, C.\u00a0Fiebig, J.\u00a0Amann, C.\u00a0Kreiter, T.\u00a0Sahr und J.\u00a0Braun geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}